Revolutionizing Pancreatic Cancer Care: How Molecular Profiling Paves the Way for Innovative Treatments

A Journey of Hope: Rick Baker’s Battle with Pancreatic Cancer

In the face of adversity, the story of Rick Baker and his wife, Shelley, exemplifies resilience and determination against a devastating diagnosis. On February 16, 2016, their lives were forever altered when Rick was diagnosed with stage IV pancreatic adenocarcinoma. Despite leading a healthy lifestyle, he faced a formidable 5 cm tumor on his pancreas and extensive liver metastases. Their journey underscores the importance of research, innovative treatments, and unwavering hope.

The Power of Research and Molecular Profiling

Upon receiving the distressing diagnosis, Rick and Shelley embarked on a mission to uncover every possible treatment option. Their research led them to molecular profiling, revealing critical genetic mutations within Rick’s cancer. Notably, he had a ROS1 fusion rearrangement, a somatic BRCA2 mutation, and the absence of KRAS.

Rick began his treatment journey in London, Ontario, under the guidance of Dr. Stephen Welch at the London Health Sciences Centre. He enrolled in a clinical trial that combined a novel drug, demcizumab, with gemcitabine and Abraxane. Over the course of this trial, Rick completed 15 cycles before his condition progressed.

• Key interventions included:
  • Liver-directed therapy (TACE) in Germany
  • Systemic FOLFIRINOX treatments
  • Proteomic analysis by Perthera to identify future treatment options

With his condition stabilizing, Rick opted for a clinical trial involving a targeted therapy aimed at his rare genetic mutation. The drug entrectinib, a single-agent tyrosine kinase inhibitor, showed promise and allowed him to continue his active lifestyle.

Surgical Interventions and Further Innovations

Encouraged by his response to treatment, Rick underwent Whipple surgery at Johns Hopkins Hospital in Baltimore, Maryland, in summer 2017. Under the care of Dr. Christopher Wolfgang, Rick received stereotactic body radiation therapy (SBRT) before surgery, which proved challenging but ultimately successful.

Post-surgery, Rick transitioned to another targeted therapy for his ROS1 mutation. Although he initially maintained stability, the emergence of lung metastases led him to seek the expertise of Dr. Alice Shaw at Massachusetts General Hospital. She introduced him to lorlatinib, a next-generation experimental ROS1 inhibitor, which yielded remarkable results.

Rick’s cancer markers showed significant improvement, and after nearly a year of treatment, his condition remained stable. This innovative therapy enabled him to enjoy life to the fullest, celebrating milestones like their 30th wedding anniversary—a moment they once feared they wouldn’t reach.

A Message of Hope for Others

Rick’s journey through advanced cancer serves as a beacon of hope for others facing similar challenges. Shelley emphasizes the importance of knowledge, urging newly diagnosed patients to engage in molecular testing and pursue treatments tailored to their unique tumor biology.

• Takeaways for cancer patients:
  • Stay informed about your diagnosis and treatment options.
  • Connect with other patients and medical professionals.
  • Explore non-standard treatments and clinical trials.

While the fight against cancer is ongoing, each day is a victory in its own right. As they reflect on their journey, Rick and Shelley remain grateful for the time they have shared and the support they’ve received from their medical team.

Although Rick has since passed away from pancreatic cancer, his story continues to inspire hope and determination for patients navigating similar paths. His legacy serves as a reminder of the importance of seeking the best treatment options available.